Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
December 2024 Update: There is a significant development concerning eye-related side effects of Ozempic and other semaglutide drugs. Two large medical studies from Denmark presented more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two recent studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Ozempic, Wegovy, and Rybelsus Causing Eye Problems, Vision Loss
Link Between Ozempic and NAION Also Involves the Eye Disorder AION
The European Medicines Agency (EMA) confirmed the link between Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator went on to say a NAION warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic. Notably, but not surprisingly, the EMA did not mention the lesser-known eye disorder AION (anterior ischemic optic neuropathy) concerning the semaglutide drug label changes.
An excerpt from a Survey of Ophthalmology medical journal article explains the relationship between NAION and AION:
To read more of this article, click below:
Anterior ischemic optic neuropathy (AION) results from ischemic damage to the anterior portion of the optic nerve, a region primarily supplied by the posterior ciliary artery circulation. Anterior ischemic optic neuropathy is divided into two types: arteritic AION (AAION), secondary to vasculitis (especially giant cell arteritis), and nonarteritic AION (NAION), secondary to non-inflammatory small vessel disease. NAION constitutes 95% of all AION and is the most common cause of acute optic neuropathy in people over the age of 50…. [Footnotes omitted.]
Given this relationship between NAION and AION, we should keep in mind that a person using Rybelsus, Wegovy, or Ozempic diagnosed with AION might have NAION as a side effect of their semaglutide-containing drug.
In turn, a person diagnosed with AION while using Ozempic, Wegovy, or Rybelsus could have a potential drug injury lawsuit to file against Novo Nordisk, the responsible pharmaceutical company, even though there was no specific mention of NAION by their eye doctor.
More information about these NAION lawsuits against the drug company is outlined in our prior article, “Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025“.
If you have been diagnosed with AION or NAION, we can assist you with a possible drug injury lawsuit that would be filed against Novo Nordisk, the responsible pharmaceutical company. To get started, you can complete our online Case Evaluation Form, or you can call attorney Tom Lamb (910-256-2971) to discuss your possible case.
[Read the article in full at source]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages